MX2022010816A - Composiciones y métodos para evaluar la eficacia de los inhibidores de los transportadores de neurotransmisores. - Google Patents

Composiciones y métodos para evaluar la eficacia de los inhibidores de los transportadores de neurotransmisores.

Info

Publication number
MX2022010816A
MX2022010816A MX2022010816A MX2022010816A MX2022010816A MX 2022010816 A MX2022010816 A MX 2022010816A MX 2022010816 A MX2022010816 A MX 2022010816A MX 2022010816 A MX2022010816 A MX 2022010816A MX 2022010816 A MX2022010816 A MX 2022010816A
Authority
MX
Mexico
Prior art keywords
efficacy
inhibitors
methods
assessing
compositions
Prior art date
Application number
MX2022010816A
Other languages
English (en)
Inventor
Wen Luo
Hong Sun
John W Whitaker
Zafrin Dhali
Haiping Lu
Xiaojun Li
Wilson Wu
Original Assignee
Denovo Biopharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denovo Biopharma Llc filed Critical Denovo Biopharma Llc
Publication of MX2022010816A publication Critical patent/MX2022010816A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere al campo de la farmacogenómica, que aplica uno o más biomarcadores genómicos y los métodos, dispositivos, reactivos, sistemas y kits de diagnóstico relacionados, para predecir respuestas individuales variadas tales como, por ejemplo, eficacia o efecto adverso, a agentes terapéuticos, por ejemplo, inhibidores de determinados transportadores de neurotransmisores tales como liafensina.
MX2022010816A 2020-03-06 2021-02-23 Composiciones y métodos para evaluar la eficacia de los inhibidores de los transportadores de neurotransmisores. MX2022010816A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062986603P 2020-03-06 2020-03-06
PCT/US2021/019265 WO2021178166A1 (en) 2020-03-06 2021-02-23 Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters

Publications (1)

Publication Number Publication Date
MX2022010816A true MX2022010816A (es) 2022-12-13

Family

ID=77613738

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010816A MX2022010816A (es) 2020-03-06 2021-02-23 Composiciones y métodos para evaluar la eficacia de los inhibidores de los transportadores de neurotransmisores.

Country Status (13)

Country Link
US (1) US20230193388A1 (es)
EP (1) EP4106872A4 (es)
JP (1) JP2023515665A (es)
KR (1) KR20230005816A (es)
CN (1) CN115515680A (es)
AR (1) AR121515A1 (es)
AU (1) AU2021231683A1 (es)
BR (1) BR112022017770A2 (es)
CA (1) CA3174572A1 (es)
IL (1) IL296168A (es)
MX (1) MX2022010816A (es)
TW (1) TW202146660A (es)
WO (1) WO2021178166A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114848835B (zh) * 2022-03-22 2023-08-25 暨南大学 塞来昔布的聚乙二醇修饰及连接叶酸基团的靶向药物分子及制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7901885B2 (en) * 2006-05-09 2011-03-08 Dsm Ip Assets B.V. Genes and markers in type 2 diabetes and obesity
WO2008065544A2 (en) * 2006-09-11 2008-06-05 Mcgill University Genetic predictors of risk for type 2 diabetes mellitus
WO2008106785A1 (en) * 2007-03-05 2008-09-12 Cancer Care Ontario Assessment of risk for colorectal cancer
US20170029892A1 (en) * 2009-05-29 2017-02-02 Jay L. Lombard Methods and compositions for the treatment of post-traumatic stress disorder
US8355927B2 (en) * 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
EP2710147A1 (en) * 2011-05-18 2014-03-26 Rheinische Friedrich-Wilhelms-Universität Bonn Molecular analysis of acute myeloid leukemia
US20170253928A1 (en) * 2013-03-15 2017-09-07 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
US20140274764A1 (en) * 2013-03-15 2014-09-18 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
ES2726650T3 (es) * 2014-03-14 2019-10-08 Caredx Inc Métodos de monitorización de terapias inmunosupresoras en un receptor de trasplante

Also Published As

Publication number Publication date
CA3174572A1 (en) 2021-09-10
US20230193388A1 (en) 2023-06-22
BR112022017770A2 (pt) 2022-11-29
IL296168A (en) 2022-11-01
CN115515680A (zh) 2022-12-23
AR121515A1 (es) 2022-06-08
EP4106872A4 (en) 2024-04-10
KR20230005816A (ko) 2023-01-10
AU2021231683A1 (en) 2022-09-22
TW202146660A (zh) 2021-12-16
EP4106872A1 (en) 2022-12-28
WO2021178166A1 (en) 2021-09-10
JP2023515665A (ja) 2023-04-13

Similar Documents

Publication Publication Date Title
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2021014443A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
EP4357783A3 (en) Highly sensitive system and methods for analysis of troponin
MY195720A (en) Transthyretin (Ttr) Irna Compositions and Methods of Use Thereof for Treating or Preventing Ttr-Associated Diseases
PH12014501106A1 (en) Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
WO2009029550A3 (en) Highly sensitive system and methods for analysis of prostate specific antigen (psa)
CR20140422A (es) Composiciones de enzima digestiva estable
WO2012019200A3 (en) Assay systems for determination of source contribution in a sample
GT201000088A (es) 2 -fluoro-2´desoxitetrahidrouridinas como inhibidores de citidina desaminasa
MX2019013634A (es) Composiciones y metodos para tratar cancer con mutaciones de braf atipicas.
BR112021015056A2 (pt) Inibidores específicos de complexos ltbp de tgf-beta e usos dos mesmos
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
BR112018070584A2 (pt) metodo e aparelho de gerenciamento
BR112022005711A2 (pt) Métodos e composições para tratar uma doença ou transtorno
WO2008091681A3 (en) Theramutein modulators
PH12021500008A1 (en) Transglutaminase 2 (tg2) inhibitors
MX2021001749A (es) Biomarcadores para terapia contra el cancer.
MX2022010816A (es) Composiciones y métodos para evaluar la eficacia de los inhibidores de los transportadores de neurotransmisores.
MX2016016742A (es) Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv).
BR112023021561A2 (pt) Compostos de carbóxi-benzimidazol moduladores de glp-1r
MX2008012208A (es) Metodo para tratar trastornos cognitivos y otros afines.
ECSP23012981A (es) Inhibidores de sarm1
MX2023011608A (es) Metodos para inhibir ras.
MX2023013173A (es) Degradadores de cinasa 2 dependiente de ciclina (cdk2) y sus usos.
MX2021007102A (es) Sistemas y metodos para evaluar la eficacia de agentes antipatogenos y composiciones que comprenden los mismos.